ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $42.7M invested in ProShares Ultra NASDAQ Biotechnology in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
13% more funds holding
Funds holding: 24 → 27 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
27
Holding in Top 10
1
Calls
$32.8M
Puts
$22.9M
Top Buyers
| 1 | +$4.27M | |
| 2 | +$2.95M | |
| 3 | +$1.99M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.8M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.28M |
Top Sellers
| 1 | -$1.27M | |
| 2 | -$678K | |
| 3 | -$474K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$234K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$183K |